The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells (Q46614261)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 January 2013

Language	Label	Description	Also known as
English	The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells	scientific article published on 29 January 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Elisabeth J Walsby

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

Michelle Lazenby

2

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

Chris J Pepper

3

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

Steven Knapper

4

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

Alan K Burnett

5

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

language of work or name

0 references

publication date

29 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

161

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

1

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

57-67

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

Targeting cell signaling pathways for drug discovery: an old lock needs a new key.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Heat shock protein 90 as a drug target: some like it hot.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

STI571 (Gleevec) as a paradigm for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

PI3K: downstream AKTion blocks apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Molecular genetics of human leukemias: new insights into therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Targeting heat shock proteins in cancer

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Molecular chaperones and the stress of oncogenesis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Hsp90 inhibitors as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Modulation of Akt kinase activity by binding to Hsp90

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Development and application of Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Targeting Hsp90: small-molecule inhibitors and their clinical development

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

All-trans-retinoic acid in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Natural Product Origins of Hsp90 Inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

17 AAG for HSP90 inhibition in cancer--from bench to bedside

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Overview: Translating Hsp90 Biology into Hsp90 Drugs

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

More than folding: localized functions of cytosolic chaperones

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

High constitutive expression of heat shock protein 90α in human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12215

21 January 2018

Identifiers

10.1111/BJH.12215

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 December 2017

http://europepmc.org/abstract/MED/23356405

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46614261&oldid=2122257489"